Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), is a minimally invasive procedure to replace the aortic valve without removing the old, diseased valve through open-heart surgery. In patients with severe aortic stenosis, TAVR offers an alternative to open-heart surgery, which is a higher-risk procedure for many elderly patients or patients with multiple co-morbidities.
TAVR Procedure
In a transcatheter aortic valve replacement procedure, doctors make a small incision in the groin area or between the ribs to insert a catheter. They then thread the catheter through the blood vessels and guide it to the heart. Using imaging like echocardiograms and fluoroscopy to guide placement, doctors meticulously position a replacement valve inside the old valve. The new valve is either self-expanding or balloon expandable. Once in place, the new valve takes over the job of regulating blood flow from the heart into the main artery (aorta). This allows doctors to fix the damaged valve without stopping the heart or using a heart-lung machine as in traditional open-heart surgery. The whole procedure usually takes 1-2 hours and does not necessitate opening the chest cavity.
Patient Selection for TAVR
Not all patients with aortic valve disease are candidates for TAVR. The ideal Candidates are those who are at high or prohibitive surgical risk for open-heart surgery due to age, frailty, or multiple medical issues. Doctors thoroughly evaluate each patient's case through diagnostic tests and risk-scoring tools to determine if TAVR can be performed safely. In general, patients who are deemed ineligible have:
Significant clarification of the ascending aorta: This makes threading the catheter more risky.
Uncorrected bleeding disorders: These increase the risk of complications.
Active endocarditis: This requires antibiotics before replacing the valve.
Severe renal impairment: The contrast dye used can further damage kidneys.
Liver failure: This precludes anticoagulation needed after the procedure.
Bicuspid aortic valves: The anatomy is less suited for TAVR than tricuspid valves.
Outcomes of TAVR
Several large clinical trials have shown TAVR to be as effective as open-heart surgery in high-risk patients. Some key outcomes from these studies include:
30-day mortality: TAVR was associated with significantly lower 30-day mortality than open-heart surgery in high-risk patients (3.4% vs. 6.5% in PARTNER Trial A).
1-year survival: 1-year survival rates were comparable between TAVR and surgical replacement groups (71.6% vs. 68.0% in PARTNER Trial B).
Improvement in symptoms: The majority of patients experienced relief from breathlessness and chest pain post-TAVR.
Durability of valves: 5-year data shows TAVR valves holding up well with low rates of structural deterioration or valve dysfunction.
Stroke risk: TAVR carries a slightly higher risk of stroke within 30 days (5.5% vs. 2.4% in Partner Trial A), but this declined with experience. Careful patient selection and improved techniques have further lowered this risk.
Patient Experience with TAVR
Most patients who undergo TAVR report an easier recovery than open-heart surgery, with a quicker return to daily activities. Some key points about the Patient experiences include:
Short hospital stay: Average hospital stay post-TAVR is just 1-4 days compared to 5-7 days for surgery. Earlier mobilization is possible.
Less pain: TAVR is less invasive and does not require stopping the heart or use of a sternotomy or heart-lung machine. Therefore, patients experience less post-procedure pain.
Rapid recovery: Most patients feel improved within days and can resume regular lifestyle within 2-4 weeks on average. Driving and light exercises may be allowed within 1-2 weeks.
Better Quality of Life : Long-term studies show TAVR maintaining quality of life better than surgery due to less physiological stress on the body from avoided heart-lung machine and sternotomy.
Minimal scarring: The small groin or rib incisions heal well with minimal scarring compared to open-heart surgery.
Future Directions
Continued refinements in valve technology, delivery systems, and techniques will help expand the indications for TAVR. Ongoing research focuses on developing:
Smaller delivery catheters and systems: This will make TAVR applicable for smaller vessels and complex anatomy.
Alternative access sites: Transaortic, transapical and transseptal approaches attempt to avoid groin complications.
Valves tailored for specific anatomies: like valves for bicuspid aortic valves or failed surgical bioprostheses.
Transcatheter mitral and tricuspid valve therapies: Early feasibility trials look promising for repair or replacement of other valves.
TAVR has revolutionized the treatment of aortic stenosis by providing a minimally invasive alternative to high-risk patients. While long-term durability is still under study, it has emerged as the standard of care for symptomatic severe aortic stenosis in most patients. Continued advances will further expand the reach of this life-saving technology
Check Report in this language
· Japanese
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages. information and technology, healthcare, chemicals and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
